Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.
The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.
Apotex has asked the US Supreme Court to reconsider a US Court of Appeals for the Federal Circuit ruling upholding four of Teva Pharmaceutical’s cancer drug patents.
A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.
Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.
The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.